Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

McKesson
Mallinckrodt
Moodys
McKinsey
Johnson and Johnson
Medtronic

Last Updated: May 26, 2022

CLINICAL TRIALS PROFILE FOR FLUOCINONIDE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Fluocinonide

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00297011 ↗ Valacyclovir+Temovate Gel for the Treatment of Herpes Labialis Completed GlaxoSmithKline Phase 2 2004-09-01 A randomized study comparing the combination of valacyclovir and temovate gel (clobetasol gel) versus placebo for the treatment of recurrent herpes labialis (cold sores).
NCT00297011 ↗ Valacyclovir+Temovate Gel for the Treatment of Herpes Labialis Completed University of Utah Phase 2 2004-09-01 A randomized study comparing the combination of valacyclovir and temovate gel (clobetasol gel) versus placebo for the treatment of recurrent herpes labialis (cold sores).
NCT00667589 ↗ Sorafenib-induced Hand- Foot Skin Reaction Treatment Terminated Bayer Phase 2 2008-06-01 The purpose of this study is to evaluate treatments for a rash caused by sorafenib.
NCT00667589 ↗ Sorafenib-induced Hand- Foot Skin Reaction Treatment Terminated Northwestern University Phase 2 2008-06-01 The purpose of this study is to evaluate treatments for a rash caused by sorafenib.
NCT00819507 ↗ VANOS Cream and Skin Barrier Function Completed Medicis Pharmaceutical Corporation Phase 4 2009-01-01 The purpose of this study is to determine the effect of short-term therapy using "VANOS Cream," a super-potent topical steroid cream on skin barrier function in patients with atopic dermatitis. This cream is already approved for this indication, but the investigators will further examine its effects on the skin barrier. This cream is a novel formulation of fluocinonide designed to enhance compliance with a cream base, but have the skin barrier repair properties of an ointment.
NCT00819507 ↗ VANOS Cream and Skin Barrier Function Completed Oregon Health and Science University Phase 4 2009-01-01 The purpose of this study is to determine the effect of short-term therapy using "VANOS Cream," a super-potent topical steroid cream on skin barrier function in patients with atopic dermatitis. This cream is already approved for this indication, but the investigators will further examine its effects on the skin barrier. This cream is a novel formulation of fluocinonide designed to enhance compliance with a cream base, but have the skin barrier repair properties of an ointment.
NCT01049243 ↗ A Study Evaluating the Efficacy of Fluocinonide Cream 0.1% (Vanos) in Subjects With Atopic Dermatitis Completed Medicis Pharmaceutical Corporation Phase 4 2009-03-01 The purpose of this research study is to better understand how fluocinonide cream 0.1% (VanosĀ®) works when people use it to treat atopic dermatitis for just a few days.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Fluocinonide

Condition Name

Condition Name for Fluocinonide
Intervention Trials
Atopic Dermatitis 3
Psoriasis 1
Rash 1
Breast Carcinoma 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Fluocinonide
Intervention Trials
Eczema 3
Dermatitis, Atopic 3
Dermatitis 3
Psoriasis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Fluocinonide

Trials by Country

Trials by Country for Fluocinonide
Location Trials
United States 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Fluocinonide
Location Trials
North Carolina 3
Oregon 2
Illinois 1
Utah 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Fluocinonide

Clinical Trial Phase

Clinical Trial Phase for Fluocinonide
Clinical Trial Phase Trials
Phase 4 2
Phase 2 4
N/A 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Fluocinonide
Clinical Trial Phase Trials
Completed 6
Terminated 1
Withdrawn 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Fluocinonide

Sponsor Name

Sponsor Name for Fluocinonide
Sponsor Trials
Medicis Pharmaceutical Corporation 3
Wake Forest University Health Sciences need to be deleted 2
Wake Forest University 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Fluocinonide
Sponsor Trials
Other 11
Industry 7
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Harvard Business School
Dow
AstraZeneca
Boehringer Ingelheim
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.